CN117701456A - Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease - Google Patents
Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease Download PDFInfo
- Publication number
- CN117701456A CN117701456A CN202311774803.8A CN202311774803A CN117701456A CN 117701456 A CN117701456 A CN 117701456A CN 202311774803 A CN202311774803 A CN 202311774803A CN 117701456 A CN117701456 A CN 117701456A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- sperm
- reduced
- reproductive
- enteritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 56
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 56
- 230000006378 damage Effects 0.000 title claims abstract description 34
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 30
- 208000014674 injury Diseases 0.000 title claims abstract description 30
- 230000001850 reproductive effect Effects 0.000 title claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
- 201000010099 disease Diseases 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 28
- 208000004232 Enteritis Diseases 0.000 claims description 31
- 230000002829 reductive effect Effects 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 9
- 238000006073 displacement reaction Methods 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 208000017443 reproductive system disease Diseases 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 210000004994 reproductive system Anatomy 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 238000009098 adjuvant therapy Methods 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 231100000469 sperm hypomotility Toxicity 0.000 claims description 3
- 238000011278 co-treatment Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 13
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 13
- 230000019100 sperm motility Effects 0.000 abstract description 9
- 210000004400 mucous membrane Anatomy 0.000 abstract description 8
- 230000033001 locomotion Effects 0.000 abstract description 6
- 230000008595 infiltration Effects 0.000 abstract description 5
- 238000001764 infiltration Methods 0.000 abstract description 5
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 230000008719 thickening Effects 0.000 abstract description 5
- 206010018691 Granuloma Diseases 0.000 abstract description 4
- 210000003979 eosinophil Anatomy 0.000 abstract description 4
- 210000000440 neutrophil Anatomy 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000003387 muscular Effects 0.000 abstract description 3
- 230000004899 motility Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 229920003045 dextran sodium sulfate Polymers 0.000 description 14
- 241000186000 Bifidobacterium Species 0.000 description 10
- 238000002791 soaking Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 7
- 239000002068 microbial inoculum Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 231100000521 sperm damage Toxicity 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010036774 Proctitis Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 238000009612 semen analysis Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 210000004783 epithelial tight junction Anatomy 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241001430332 Bifidobacteriaceae Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003883 azoospermia Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000528 oligospermia Toxicity 0.000 description 2
- 208000008634 oligospermia Diseases 0.000 description 2
- 230000036616 oligospermia Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010017912 Gastroenteritis radiation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 206010039954 Seminal vesiculitis Diseases 0.000 description 1
- 208000036379 Sigmoiditis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000011140 intestinal infectious disease Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020624 radiation proctitis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000281 testicular toxicity Toxicity 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses bifidobacterium lactis, a preparation thereof and application thereof in the field of biological medicine technology, and relates to the field of biological medicine technology. The Latin theory of the bifidobacterium lactis is as followsBifidobacterium lactis BB-10ABC, accession numberIs CCTCC NO: M2019011. The bifidobacterium lactis can obviously reduce the inflammatory infiltration level of neutrophils and eosinophils, reduce crypt granuloma, improve the damage of the crypt structure of mucous membrane and the thickening of mucous membrane muscular layer, improve the sperm motility, the motility rate and the sperm related movement parameter level, improve the intestinal microenvironment and reduce the sperm injury. The invention provides a reliable theoretical basis for improving the quality reduction of male sperms caused by ulcerative colitis, and has important significance and wide application prospect.
Description
Technical Field
The invention relates to the technical field of biological medicine, in particular to bifidobacterium lactis, a preparation thereof and application thereof in reproductive injury or diseases.
Background
Inflammatory bowel disease (Inflammatory Bowel Diseases, IBD) is a chronic inflammatory disease of unknown etiology, including Ulcerative Colitis (UC) and Crohn's Disease (CD). Ulcerative colitis mainly involves the rectum and sigmoid colon, is localized to the colonic mucosal and submucosal layers, is continuously distributed, and slowly and repeatedly attacks. Clinically, abdominal pain, diarrhea, purulent bloody stool and the like are mainly manifested. At present, the treatment of ulcerative colitis is still mainly anti-inflammatory and immunoregulation, and the following 6 types of commonly used medicines are available: aminosalicylic acids, glucocorticoids, immunosuppressants, biologicals, probiotics and anti-infective agents. However, the above-mentioned drug treatments have problems of large side effects, high price, etc.
In the prior art, the enteritis can negatively affect male reproductive system, parmar et al research on the effect of ulcerative colitis on testes, and research finds that the ulcerative colitis is related to testis injury, can lead to DNA injury and sperm DNA injury of testes, and the number of epididymal sperms is obviously reduced, (A R Parmar, P Trivedi, G B Jena, dextran sulfate sodium-induced ulcerative colitis leads to testicular toxicity in mice: role of inflammation, oxidative stress and DNA damage, reprod Toxicol, 2014, 49:171-84.).
Bifidobacteria are gram-positive anaerobic bacteria, a spore-free, non-mobile bacillus, usually in the form of a curve, rod, widely found in the digestive tract of humans and animals, but varying with age and growth environment. Bifidobacteria are a member of the family bifidobacteriaceae, belonging to the phylum actinomycota, and were first isolated from breast-fed infant feces by Tissier in 1899 and have been shown to be one of the major bacterial members of the intestinal microbiota of breast-fed infants (Turroni F, duranti S, bottacini F, et al Bifidobacterium bifidum as an example of a specialized human gut commensal [ J ]. Frontiers in microbiology, 2014, 5:437.).
The prior art discloses that bifidobacterium lactis strain BB01 can induce rapid and sustained enhancement of intestinal epithelial tight junction function in a TLR-2 and P38 kinase dependent manner and protect the intestinal epithelial tight junction barrier in a TLR-2 dependent manner, thereby preventing Dextran Sodium Sulfate (DSS) -induced colitis (Al-Sadi R, dharmamarakash V, nighot P, et Al Bifidobacterium bifidum enhances the intestinal epithelial tight junction barrier and protects against intestinal inflammation by targeting the toll-like receptor-2 pathway in an nf- κb-independent manner [ J ]. International Journal of Molecular Sciences, 2021, 22 (15): 8070.). However, further anti-inflammatory mechanisms and mechanisms of intestinal-testosterone intervention for bifidobacterium lactis strain BB01 remain to be discussed.
Disclosure of Invention
The object of the present invention is to provide bifidobacterium lactis, formulations thereof and use thereof in the treatment of reproductive lesions or disorders.
In the present invention, "Bifidobacterium lactis BB01", "Bifidobacterium lactis BB-10ABC", "and"Bifidobacterium lactisBB01”、“Bifidobacterium lactisBB-10ABC "refers to bifidobacterium lactis with the preservation number of CCTCC NO: M2019011.
In order to achieve the above object, the present invention has the following technical scheme:
in one aspect, the present invention provides a bifidobacterium lactis BB01, which has the Latin chemical nameBifidobacterium lactisBB-10ABC with the preservation number of CCTCC NO: M2019011.
The genus bifidobacterium is a member of the family bifidobacteriaceae, belonging to the phylum actinomycota. Bifidobacteria are gram-positive anaerobic bacteria, a spore-free, non-mobile bacillus, usually in the form of a curved, rod, widely found in the digestive tract of humans and animals.
In yet another aspect, the present invention provides a microbial agent comprising bifidobacterium lactis BB01 as described above.
According to some embodiments of the invention, the microbial inoculum may further comprise a preparation of bifidobacterium lactis BB01.
Further, the preparation is one or more of culture, fermentation liquor and fermentation liquor sediment.
Still further, the culture is obtained by inoculating bifidobacterium lactis into a culture medium.
Further, the culture medium is one or more of MRS culture medium, MC culture medium and BCP culture medium.
Specifically, the microbial inoculum is powder or liquid preparation.
In particular, the microbial agents may be in solid, liquid, semi-solid or any physical form available to those skilled in the art through current or future-occurring techniques that comprise the necessary active ingredients to achieve any of the uses, functions or effects of the present invention.
For some embodiments, the microbial agent is in solid form. Specifically, the powder may be a lyophilized powder.
In particular, the method of preparing the lyophilized powder may be a method currently used conventionally in the art, or may be other methods that may occur in the future to obtain a solid form of the microorganism or the microorganism culture, and it should be clarified that the method of preparing the lyophilized powder should not be a condition limiting the scope of the present invention.
In a further aspect, the invention provides an application of the bifidobacterium lactis BB01 or the microbial inoculum in preparing a medicament for treating, preventing or assisting in treating a reproductive system disease.
Specifically, the reproductive system diseases comprise inflammation-induced male reproductive injury, smoking or alcoholism-induced male reproductive injury, drug-induced male reproductive injury, environmental factor-induced male reproductive injury and obesity-induced male reproductive injury.
Specifically, the inflammation includes enteritis, prostatitis, orchitis, epididymitis, seminal vesiculitis and urethritis.
In particular, the environmental factors include excess PM in the environment 2.5 、PM 10 Sulfur dioxide, nitrogen dioxide, polycyclic aromatic hydrocarbon compounds, phthalate compounds, and electromagnetic radiation.
In particular, the reproductive system disease is male reproductive injury induced by enteritis.
More specifically, the male reproductive injury is one or more of oligospermia, sperm motility decrease, testis tissue injury, sperm head side swing amplitude decrease, sperm linearity decrease, whipping frequency decrease, average angular displacement decrease, forward direction decrease, linear movement speed decrease, average path speed decrease and curve speed decrease.
More specifically, the enteritis is ulcerative colitis.
Still further particularly, the symptoms of ulcerative colitis are weight loss, bloody stool, soft stool, and rotten stool.
In still another aspect, the invention provides an application of the bifidobacterium lactis BB01 or the microbial inoculum in preparing a medicament for treating, preventing or assisting in treating enteritis.
Specifically, the bifidobacterium lactis BB01 or the microbial inoculum reduces the granuloma of the crypt by reducing the inflammatory infiltration level of neutrophils and eosinophils, improves the damage of the crypt structure of the mucous membrane and the thickening of the muscular layer of the mucous membrane, improves the sperm motility and the sperm quality, and improves the ulcerative colitis.
In particular, the enteritis includes, but is not limited to, enteritis, colitis and proctitis.
Further specifically, the enteritis includes, but is not limited to, viral enteritis and bacterial enteritis.
Further specifically, the colitis includes, but is not limited to, ulcerative colitis, ischemic colitis, sigmoiditis, pseudomembranous colitis.
Still more particularly, the colitis is ulcerative colitis.
Further specifically, the proctitis include, but are not limited to, acute proctitis, chronic proctitis, tuberculous proctitis, and radiation proctitis.
In particular, the medicine can be prepared into a loaded bifidobacterium lactis BB01 #Bifidobacterium bifidumAny form of formulation of BB 01).
Preferably, the medicament may comprise a pharmaceutically acceptable carrier.
Further, the pharmaceutically acceptable carrier includes, but is not limited to, excipients, buffers, emulsifiers, stabilizers, diluents, binders, preservatives.
Specifically, the excipient is at least one selected from microcrystalline cellulose, lactose, pregelatinized starch, cyclodextrin, carboxymethyl cellulose and mannitol.
Specifically, the buffer is at least one selected from sodium dihydrogen phosphate, sodium bicarbonate, ammonium bicarbonate, sodium acetate, citrate, histidine and succinate.
Specifically, the emulsifier is at least one selected from magnesium stearate, zinc stearate, calcium stearate, glyceryl stearate, sorbitan isostearate, sorbitan oleate, glycerol oleate and polyglycerol-3 polyricinoleate.
Specifically, the stabilizer is at least one selected from acacia, agar, alginic acid, cellulose ether and carboxymethyl chitin.
Specifically, the diluent is at least one selected from erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate and crystalline cellulose.
Specifically, the binder is at least one selected from ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, sodium alginate and polyvinylpyrrolidone.
Specifically, the preservative is at least one selected from methyl hydroxybenzoate, propyl hydroxybenzoate, methyl paraben, ethyl paraben, propyl paraben, chlorobutanol, thimerosal, mercuric oxide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride and ethyl hydroxybenzoate.
In yet another aspect, the present invention provides a medicament for the treatment, prevention or adjuvant treatment of a disease of the reproductive system, said medicament comprising bifidobacterium lactis BB01 as described above or a bacterial agent as described above.
Preferably, the viable count of the bifidobacterium lactis in the medicament is (0.1-10) multiplied by 10 8 CFU/ml or (0.1-10). Times.10 8 CFU/g。
Preferably, the medicine contains the bifidobacterium lactis BB01 or the microbial inoculum.
Preferably, the medicament can also comprise a pharmaceutically acceptable carrier.
Specifically, the dosage form of the medicine is any one of tablets, capsules, granules, ointments, suspensions, powders, injections, emulsions, solutions, drop pills and aerosols.
Specifically, the reproductive system diseases comprise inflammation-induced male reproductive injury, smoking or alcoholism-induced male reproductive injury, drug-induced male reproductive injury, environmental factor-induced male reproductive injury and obesity-induced male reproductive injury.
Further, the reproductive system disease is male reproductive injury induced by enteritis.
Specifically, the medicine can improve one or more of oligospermia, sperm motility decrease, testis tissue injury, sperm head side swing amplitude decrease, sperm linearity decrease, whipping frequency decrease, average angular displacement decrease, forward direction decrease, linear motion speed decrease, average path speed decrease and curve speed decrease.
In yet another aspect, the invention provides a medicament for treating, preventing or assisting in treating enteritis, wherein the medicament comprises the bifidobacterium lactis BB01 or the microbial inoculum.
Preferably, the viable count of the bifidobacterium lactis in the medicament is (0.1-10) multiplied by 10 8 CFU/ml or (0.1-10). Times.10 8 CFU/g。
The beneficial effects of the invention are as follows:
the bifidobacterium lactis BB01 provided by the inventionBifidobacteriumbifidumBB 01) can effectively relieve enteritis and male reproductive injury caused by related causes thereof, and relieve enteritis by improving male sperm motility. The interference of the bifidobacterium lactis BB01 obviously reduces the inflammatory infiltration level of neutrophils and eosinophils, reduces crypt granuloma, improves the phenomena of the damage of a mucous membrane crypt structure, the thickening of mucous membrane myometrium and the like, and obviously improves the total number, the activity rate, the vitality and the related exercise parameter level of sperms so as to relieve the reproductive injury induced by enteritis and further protect intestinal barriers. The invention provides a reliable theoretical basis for improving male reproductive injury induced by enteritis, and has important significance.
Preservation description
Preservation number: cctccc No. M2019011;
classification naming:Bifidobacterium lactisBB-10ABC；
preservation time: 2019, 1 month and 4 days;
preservation unit: china center for type culture Collection;
the preservation unit is abbreviated as: cctccc;
preservation address: eight branches of 299 Wuhan university in Wuhan district of Wuhan, hubei province.
Drawings
FIG. 1 is a H & E stained photograph of a section of colon tissue.
Fig. 2 is a colon histopathological score.
FIG. 3 shows the effect of Bifidobacterium lactis BB01 intervention on sperm morphology and density.
Figure 4 is the effect of bifidobacterium lactis BB01 intervention on sperm count.
Fig. 5 is the effect of bifidobacterium lactis BB01 intervention on sperm motility in sperm damage caused by sperm and enteritis.
FIG. 6 is the effect of Bifidobacterium lactis BB01 intervention on sperm motility in sperm damage caused by sperm and enteritis.
Fig. 7 is the effect of bifidobacterium lactis BB01 intervention on sperm head lateral swing amplitude (Amplitude of lateral head displacement, ALH) in sperm injury caused by sperm and enteritis.
Fig. 8 is the effect of bifidobacterium lactis BB01 intervention on Linearity (LIN) of sperm in sperm damage caused by sperm and enteritis.
Fig. 9 is the effect of bifidobacterium lactis BB01 intervention on the whipping frequency of sperm (Beat cross frequency, BCF) in sperm damage due to sperm and enteritis.
Fig. 10 is the effect of bifidobacterium lactis BB01 intervention on the mean angular displacement of sperm (Mean angular displacement, MAD) in sperm injury caused by sperm and enteritis.
Fig. 11 is the effect of bifidobacterium lactis BB01 intervention on sperm pre-sperm tropism (Straightness coefficient, STR) in sperm injury caused by sperm and enteritis.
FIG. 12 is a graph showing the effect of Bifidobacterium lactis BB01 intervention on the linear motility rate (VSL) of sperm in sperm damage caused by sperm and enteritis.
Figure 13 is the effect of bifidobacterium lactis BB01 intervention on the mean path rate of sperm (Average path velocity, VAP) in sperm damage caused by sperm and enteritis.
Figure 14 is the effect of bifidobacterium lactis BB01 intervention on sperm curve rate (Curvilinear velocity, VCL) in sperm injury caused by sperm and enteritis.
In the drawings, different lowercase letters are marked to indicate that the inter-group variability is remarkablep<0.05 The difference between groups indicated by the same lowercase letters is not obvious [ ]p>0.05）。
Detailed Description
In order to make the technical means, the creation features, the achievement of the purpose and the effect of the present invention easy to understand, the present invention will be further elucidated with reference to the specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all of them. Based on the examples in the embodiments, those skilled in the art can obtain other examples without making any inventive effort, which fall within the scope of the invention. In the following examples, unless otherwise specified, the methods of operation used were conventional, the equipment used was conventional, and the materials used in the examples were the same.
Basic example separation and purification and identification of bifidobacterium lactis BB01
1. Preparation of experiments
1. Experimental materials
1.1 Instrument for measuring and controlling the intensity of light
Biological safety cabinet, gene amplification instrument, electronic pipette.
1.2 Reagent(s)
Bacteria Genomic DNA Kit (century well), 2X SanTaq PCR Mix premix, lysozyme buffer, 4S Green Plus non-toxic nucleic acid dye, proteinase K solution, DNA molecular weight standard Marker (100-2000 bp), RNase-free double distilled water, TAE buffer (all from Shanghai Biotechnology).
1.3 Consumable material
Test tubes, disposable plates, gloves, alcohol lamps, test tube racks, toothpicks, coating sticks, serum pipettes, PCR octal tubes, 1.5ml centrifuge tubes.
2. Culture medium
2.1 Isolation medium
2.1.1 Improved MRS culture medium
Table 1.
Note that: the L-cysteine solution is added after filtration and sterilization.
Wherein: the L-cysteine concentration was: 5mg/mL, 100mL was added to 1L.
2.1.2 LBS agar
Table 2.
Note that: the culture medium had a precipitate after autoclaving, shaking up and pouring into sterile dishes.
2.1.3 TPY agar
Table 3.
2.2 Enrichment medium
2.2.1 Improved MRS broth
Table 4.
2. Sample dilution and culture
1mL of the homogenized sample was immediately inoculated into 9mL of physiological saline and recorded as 10 -1 The method comprises the steps of carrying out a first treatment on the surface of the Continue the dilution down for 6 gradients, recorded as 10 -2 、10 -3 、10 -4 、10 -5 、10 -6 、10 -7 0.1ml of each concentration of the dilution was extracted, and the mixture was spread on a plate of a separation medium and cultured anaerobically at a constant temperature of 37℃for 72 hours.
3. Separation and purification
And (3) selecting different colony forms, dividing and streaking the different colony forms into different separation culture mediums, performing anaerobic culture at a constant temperature of 37 ℃ for 48 hours, performing microscopic examination on the colony forms, selecting characteristic colonies (dumbbell-shaped, Y-shaped and V-shaped) of the milk bifidobacteria, and repeatedly streaking, separating and purifying.
4. 16S identification and preservation
The purified colonies were inoculated in modified MRS broth in a sterile operation, and cultured in an anaerobic incubator at 37℃for 24 hours, with 16S identification in synchronization:
a. primer(s)
Table 5.
b. PCR system
27F primer solution 1.5. Mu.L, 1492R primer solution 1.5. Mu.L, 2 XPCR MasterMix 25. Mu.L, sterile water 20. Mu.L, template 2. Mu.L.
c. PCR reaction conditions
95 ℃ for 5min;30 cycles: 95 ℃ for 30s;55 ℃ for 30s;72 ℃ for 2min;72℃for 10min.
After NCBI comparison, the fermentation broth of bifidobacterium lactis is identified, and 25% glycerol tubes are frozen for preservation.
EXAMPLE 1 Effect of Bifidobacterium lactis BB01 on sperm damage due to sperm and enteritis
1. Experimental reagent: dextran Sodium Sulfate (DSS), purchased from MP biomedical company (MP Biomedicals LLC) in the united states.
2. Experimental animals: c57BL/6JNifdc male mice weighing 20-22g were purchased from Guangdong Venethol laboratory animal technologies Inc. (license number: SCXK (Guangdong) 2022-0063). The environment is that illumination time is 12-h alternately, the temperature is 20-25 ℃, the relative humidity is 50+/-5 percent, and experimental animals in university and south China are fed in an adaptive manner and are fed freely. The experimental operations were all performed according to the requirements related to the "Ministry of ethics of experimental animals of Nanno university".
3. The experimental method comprises the following steps:
(1) Experimental animal grouping and model establishment
The C57BL/6JNifdc male mice are adaptively fed by adopting common feed, and 4 groups of 32 mice are randomly and averagely divided by using a weight stratification method, wherein 8 mice in each group are respectively: control group, DSS group, dss+bl group (BL is low doseBifidobacterium bifidumBB01，5×10 8 CFU/ml), dss+bh group (BH is high doseBifidobacterium bifidumBB01，5×10 9 CFU/ml). A DSS colitis model was established, and animals were given free-drinking DSS solution (concentration 2%) with pure water for 8 days, followed by plain drinking water for 2 days for modeling.
(2) Intervention treatment
All groups of mice began to intervene on the first day of modeling and the intervention was completed: wherein the control group and the DSS group are respectively filled with water with corresponding volumes, and the DSS+BL group and the DSS+BH group are respectively filled with 0.2mL of bifidobacterium lactis BB01 #Bifidobacterium bifidumBB 01) intervention.
(3) Hematoxylin-eosin staining:
a. colon tissue was paraffin-embedded and sectioned at a thickness of 5 μm.
b. The slices were placed in an oven to bake slices 2h at 70 ℃.
c. Dewaxing to water: xylene soak for 10min x 3 times; soaking in absolute ethanol for 5min×2 times; soaking in 90% ethanol for 5min; soaking in 80% ethanol for 5min; soaking in 70% ethanol for 5min; soaking in deionized water for 5 min.
d. Hematoxylin was used to rapidly stain 35 s and rinsed with running water for 5 min.
e. Eosin flash stain 3 s, running water flash rinse.
f. And (3) dehydration and transparency: soaking in 70% ethanol for 2min; soaking in 80% ethanol for 2min; soaking in 90% ethanol for 2min; soaking in absolute ethanol for 3 min; xylene soak was 5min x 2 times.
g. Mixing neutral gum and fresh xylene at a ratio of 4:1, sealing, and naturally air drying.
h. And (5) photographing and analyzing.
(4) Sperm parameter determination
a. The sperm analyzer was started half an hour in advance and the sperm count plate was pre-heated at 37 ℃. Meanwhile, the water bath kettle is started for half an hour in advance to preheat the normal saline at 37 ℃.
b. The right epididymal tail is placed in 1.0 mL preheated physiological saline to be rapidly sheared, released for 5 minutes at 37 ℃, 10.0 mu L of fully mixed sperm suspension is added into a sperm counting plate, and continuous frame dynamic photographing is carried out on sperm by using a Computer-aided semen analysis system (Computer-aided Semen Analysis System, CASA) for measuring sperm motility and related parameters of movement. And then after the sperm is stationary, carrying out single-frame static photographing on the sperm for analysis of sperm quantity and morphology.
And according to the photographed pictures, the dynamic and static analysis of the sperms is carried out by combining a computer-aided semen analysis system.
4. Experimental results
The invention successfully builds a DSS colitis model, and after the DSS solution is given to animals for free drinking modeling, compared with a control group, the mouse faeces have characteristic phenotypes such as soft faeces, rotten faeces, blood faeces and the like. And the interference of the bifidobacterium lactis BB01 can effectively improve the blood and feces phenomenon.
In combination with the results of H & E staining of colon tissue sections, further pathology scoring analysis was performed on colon tissue. Compared with the control group, the colon tissue of the DSS treatment group has characteristic phenotypes such as inflammatory infiltration, crypt abscess, villus shortening and even complete disappearance, crypt structure deformation, mucosa myolayer thickening and the like (figure 1), and the colon histopathological score is remarkably increased (figure 2). While the intervention of the bifidobacterium lactis BB01 with high dosage obviously reduces the inflammatory infiltration level of neutrophils and eosinophils, reduces crypt granuloma, and improves the phenomena of the damage of the crypt structure of the mucous membrane, the thickening of the muscular layer of the mucous membrane and the like (figure 1).
The sperm morphology and function are thoroughly discussed by using a computer-aided semen analysis system. Compared to the control group, DSS treated groups showed significant reproductive lesions: sperm count (fig. 4) and density (fig. 3) were significantly reduced, sperm motility (fig. 5), sperm motility (fig. 6), sperm head lateral swing amplitude (fig. 7), whipping frequency (fig. 9), average angular displacement were all significantly reduced (fig. 10), sperm linearity was not significantly changed (fig. 8), handedness was not significantly changed (fig. 11), linear movement rate (fig. 12), average path rate (fig. 13), and curve rate (fig. 14) were all significantly slowed down. While bifidobacterium lactis BB01 intervention significantly improved sperm motility and sperm-associated kinetic parameter levels (head-to-side amplitude, whipping frequency, mean angular displacement, linear movement rate, mean path rate, and curve rate) in reproductive lesions caused by enteritis, low doses of bifidobacterium lactis BB01 significantly improved sperm number and density. The invention points out the effect of bifidobacterium lactis BB01 in treating and/or preventing male reproductive injury caused by enteritis, and discovers that bifidobacterium lactis BB01 can be used as a protective component for improving the activity of male sperms and improving the male reproductive injury.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (10)
1. Bifidobacterium lactis BB01, latin's nameBifidobacterium lactis BB-10ABC, which is characterized in that the preservation number is CCTCC NO: M2019011.
2. A microbial agent comprising bifidobacterium lactis BB01 of claim 1.
3. Use of bifidobacterium lactis BB01 of claim 1 or the microbial agent of claim 2 for the manufacture of a medicament for the treatment, prophylaxis or co-treatment of a reproductive system disorder.
4. The use according to claim 3, wherein said disorder of the reproductive system comprises inflammation-induced male reproductive lesions, smoking-or alcoholism-induced male reproductive lesions, drug-induced male reproductive lesions, environmental factor-induced male reproductive lesions and obesity-induced male reproductive lesions.
5. The use according to claim 4, wherein the disorder of the reproductive system is enteritis-induced male reproductive lesions.
6. The use of claim 5, wherein the male reproductive injury is one or more of reduced sperm count, reduced sperm motility, damaged testis tissue, reduced sperm head lateral swing amplitude, reduced sperm linearity, reduced whipping frequency, reduced average angular displacement, reduced handedness, reduced linear velocity, reduced average path velocity, reduced curve velocity.
7. Use of bifidobacterium lactis BB01 of claim 1 or the microbial agent of claim 2 for the manufacture of a medicament for the treatment, prophylaxis or co-treatment of enteritis.
8. A medicament for the treatment, prevention or adjuvant therapy of a disease of the reproductive system, characterized in that it comprises bifidobacterium lactis BB01 according to claim 1 or the bacterial agent according to claim 2.
9. The medicine according to claim 8, wherein the viable count of bifidobacterium lactis in the medicine is (0.1-10) ×10 8 CFU/ml or (0.1-10). Times.10 8 CFU/g。
10. A medicament for the treatment, prevention or adjuvant therapy of enteritis, characterized in that it comprises bifidobacterium lactis BB01 according to claim 1 or the bacterial agent according to claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311774803.8A CN117701456A (en) | 2023-12-22 | 2023-12-22 | Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311774803.8A CN117701456A (en) | 2023-12-22 | 2023-12-22 | Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117701456A true CN117701456A (en) | 2024-03-15 |
Family
ID=90147778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311774803.8A Pending CN117701456A (en) | 2023-12-22 | 2023-12-22 | Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117701456A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107636146A (en) * | 2015-03-02 | 2018-01-26 | 同生公司 | It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up |
| US20230069454A1 (en) * | 2021-09-01 | 2023-03-02 | Harbin Sunflower Pharmaceutical Co., Ltd. | Bifidobacterium lactis strain for preventing or treating colitis and use thereof |
| CN116144536A (en) * | 2022-12-23 | 2023-05-23 | 中科宜康（北京）生物科技有限公司 | Composite probiotics fermentation composition for improving male sperm motility and application |
| CN117070409A (en) * | 2023-08-11 | 2023-11-17 | 苏州普瑞森生物科技有限公司 | Bacterium of bifidobacterium animalis subspecies lactis and application thereof in inflammatory bowel disease |
| CN117535175A (en) * | 2023-10-12 | 2024-02-09 | 善恩康生物科技（苏州）有限公司 | Composite probiotics and application thereof in preparation of products for preventing or assisting in treating colorectal cancer |
-
2023
- 2023-12-22 CN CN202311774803.8A patent/CN117701456A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107636146A (en) * | 2015-03-02 | 2018-01-26 | 同生公司 | It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up |
| US20230069454A1 (en) * | 2021-09-01 | 2023-03-02 | Harbin Sunflower Pharmaceutical Co., Ltd. | Bifidobacterium lactis strain for preventing or treating colitis and use thereof |
| CN116144536A (en) * | 2022-12-23 | 2023-05-23 | 中科宜康（北京）生物科技有限公司 | Composite probiotics fermentation composition for improving male sperm motility and application |
| CN117070409A (en) * | 2023-08-11 | 2023-11-17 | 苏州普瑞森生物科技有限公司 | Bacterium of bifidobacterium animalis subspecies lactis and application thereof in inflammatory bowel disease |
| CN117535175A (en) * | 2023-10-12 | 2024-02-09 | 善恩康生物科技（苏州）有限公司 | Composite probiotics and application thereof in preparation of products for preventing or assisting in treating colorectal cancer |
Non-Patent Citations (2)
| Title |
|---|
| FENG T等: "Microorganisms in the reproductive system and probiotic\'s regulatory effects on reproductive health", COMPUT STRUCT BIOTECHNOL J, vol. 20, 30 March 2022 (2022-03-30), pages 1541 - 1553 * |
| 孙庆申等: "双歧杆菌及其产品缓解肠炎症状的研究进展", 乳业科学与技术, vol. 43, no. 4, 1 July 2020 (2020-07-01), pages 29 - 33 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022100633A1 (en) | Lactobacillus gasseri for prevention and/or treatment of reproductive tract flora disorder-related diseases | |
| CN114574390B (en) | Bifidobacterium longum subspecies infantis for relieving colonitis and application thereof | |
| Yan et al. | Bifidobacterium longum subsp. longum YS108R fermented milk alleviates DSS induced colitis via anti-inflammation, mucosal barrier maintenance and gut microbiota modulation | |
| CN112760247B (en) | Lactobacillus rhamnosus for preventing and/or treating diseases caused by genital tract flora disorder and/or bone loss | |
| WO2017020784A1 (en) | Bacteroides fragilis and application thereof | |
| CN109628359B (en) | Lactobacillus reuteri capable of relieving allergic asthma and application thereof | |
| CN110643542B (en) | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof | |
| CN113832077B (en) | Lactobacillus rhamnosus and application thereof | |
| CN112458007A (en) | Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder | |
| CN113122466B (en) | Enterococcus faecalis and application thereof | |
| CN114292781B (en) | Bifidobacterium longum SYSU-02 and application thereof | |
| CN115851500B (en) | Lactobacillus plantarum and application thereof | |
| CN111281895A (en) | Lactic acid bacteria for treating colitis and application thereof | |
| CN114231470A (en) | Lactobacillus acidophilus capable of relieving ulcerative colitis and application thereof | |
| CN115505551B (en) | Lactobacillus helveticus and application thereof in preventing or treating nephritis | |
| CN111117925B (en) | Anerostipes sp B2131 bacterium and application thereof in inflammatory bowel disease | |
| CN114107133A (en) | Enterococcus faecium for resisting rectal tumors and application thereof | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| CN114854638A (en) | Lactobacillus paracasei for relieving colitis by efficiently expressing adenosine deaminase | |
| CN117264814A (en) | Lactobacillus rhamnosus with effects of preventing and treating digestive tract diseases | |
| WO2017020783A1 (en) | Application of bacteroides fragilis in prevention and/or treatment of meningitis | |
| CN116004416B (en) | Application of bifidobacterium bifidum from infant intestinal tract | |
| CN117701456A (en) | Bifidobacterium lactis, preparation thereof and application thereof in reproductive injury or disease | |
| CN111304120B (en) | Application of Blautia sp B2132 bacterium in prevention and/or treatment of inflammatory bowel disease | |
| CN115418332A (en) | Lactobacillus plantarum capable of preventing and improving chemical liver injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |